Flu A+B
BD Veritor™ Plus System
Influenza A + B rapid antigen testing
Be ready for flu outbreaks
Seasonal flu outbreaks are routinely caused by the two main types of influenza, A and B, and account for 3-5 million cases of severe illnesses per year and up to 650,000 deaths worldwide¹.
During the flu season, certain people, including children under five, pregnant women and the elderly are at risk of being hospitalized for flu-related complications¹.
Accurate detection and diagnosis of flu and beginning a regimen of influenza antiviral drugs within the first 48 hours of symptom onset, are important for the most effective treatment².
BD Veritor™ Plus System
for Flu A + B
The BD Veritor™ System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay.
The system provides rapid, reliable results, and offers one-button functionality for workflow flexibility, allowing health care providers to confidently use the Analyzer.
Simple sample collection with nasal and nasopharyngeal swabs3-4
Fast, reliable results in as few as 11 minutes3-4
Dual testing capability distinguishes Flu A from Flu B
Two analysis options to optimize workflow
The BD Veritor™ System for Rapid Detection of Flu A+B assay products meet the FDA Class II special controls applicable to RIDTs for analytical reactivity testing.
Rapid flu test clinical performance data
We know that a test is only as good as the reliability of its results. We compared the performance of the BD Veritor™ System for Rapid Detection of Flu A+B test to an FDA-cleared Influenza A and B molecular assay (PCR) ³.
Comparison of BD Veritor™ System for Rapid Detection of Flu A+B Test to PCR
Data shows a high comparative positive percent agreement, and a high negative percent agreement — both of which indicate the reliability of the BD Veritor™ Plus System.
BD Flu A Clinical Kit
83.0%
Positive Percent Agreement
(95% C.I 78.0-87.0%)
97.6%
Negative Percent Agreement
(95% C.I 96.6-98.3%)
BD Flu A Clinical Kit3,4
REFERENCE PCR
BD Veritor TM
| P | N | Total | |
|---|---|---|---|
| P | 224 | 29 | 253 |
| N | 46 | 1,172 | 1,218 |
| Total | 270 | 1,201 | 1,471 |
Reference method : PCR
Sensitiivity : 83.0% (95% CI: 78.0-87.0%)
Specificity : 97.6% (95% CI: 96.6-98.3%)
BD Flu B Clinical Kit
81.3%
Positive Percent Agreement
(95% C.I 72.1-88.0%)
99.8%
Negative Percent Agreement
(95% C.I 99.4-99.9%)
BD Flu B Clinical Kit3,4
REFERENCE PCR
BD Veritor TM
| P | N | Total | |
|---|---|---|---|
| P | 74 | 3 | 77 |
| N | 17 | 1,377 | 1,394 |
| Total | 91 | 1,380 | 1,471 |
Reference method : PCR
Sensitiivity : 81.3% (95% CI: 72.1-88.0%)
Specificity : 99.8% (95% CI: 99.4-99.9%)
Explanation of Terms:
Positive percent agreement (PPA) indicates the proportion of individuals who tested flu positive with PCR that also test positive with the antigen test
Negative percent agreement (NPA) indicates the proportion of individuals who tested flu negative with PCR that also tested flu negative with the antigen test
P: Positive
N: Negative
C.I.: Confidence Interval
Clinical Performance NP Washes/Aspirates 2010–2011:
Performance characteristics for the BD VeritorTM System for Rapid Detection of Flu A+B test were established using NP wash/aspirate specimens in multi-center clinical studies conducted at two U.S. trial sites and one Hong Kong trial site during the 2010–2011 respiratory season. A total of 1502 prospective specimens (1002 in the U.S and 500 in Hong Kong) were evaluated using the BD VeritorTM System for Rapid Detection of Flu A+B test and PCR. Five specimens were not evaluable because of data reconciliation issues, an additional 13 were excluded because of insufficient sample volume for reference method testing and 13 samples were excluded as “Result Invalid” (for an invalid rate of 0.9% [13/1,484]).
The prospective specimens consisted of NP washes and aspirates from symptomatic patients. 49% of the samples were from females and 51% from males. 56.6% were from patients less than or equal to 5 years of age. 21.9% of the patients tested were in the 6–21year age group, 5.7% were from 22–59 years of age and 15.8% were obtained from people greater than or equal to age 60 (the patient age was not provided for 0.1% of samples). 3,4
Reference Method: PCR PPA: 81.3% (95% C.I. 72.1–88.0%) NPA: 99.8% (95% C.I. 99.4–99.9%)
BD Veritor™ Plus System ordering and reimbursement
As your facility continues to provide valuable rapid diagnostic testing, you may need to reorder. Please click here for more information.
REFERENCES
- www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed December 19, 2018
- Flu Treatment. CDC. https://www.cdc.gov/flu/treatment/index.html
- BD Veritor System for Rapid Detection of Flu A+B, CLIA-waived kit [package insert], 8087667. Franklin Lakes, NJ: Becton, Dickinson and Company.
- BD Veritor System for Rapid Detection of Flu A+B, laboratory kit [package insert], 8087666. Franklin Lakes, NJ: Becton, Dickinson and Company.
Contact Us
To request a demo or for more information on our products contact our Sales Representatives
Contact UsSupport
For training, equipment servicing and more, contact our Customer Success team
Contact Support